MET-4

Phase 3Small molecule

UUniversity Health Network, Toronto

MET-4 is one of 89 small molecule programs targeting Squamous Cell Carcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Squamous Cell CarcinomaActive, not recruiting

ImmunotherapyActive, not recruiting

Squamous Cell CarcinomaPreclinical

Active, not recruiting

ImmunotherapyPhase 3

Active, not recruiting

Competition

Competitive Landscape

84 competitors in Immunotherapy

#DrugCompanyPhaseTrials

Opdivo

Bristol-Myers Squibb

Phase 3

22 2

Keytruda

Merck & Co.

Phase 3

18 3

Tecentriq

Roche

Phase 3

10 4

Taxol

Teva

Phase 3

3 5

Gazyva

Roche

Phase 3

1 6

Calquence

AstraZeneca

Phase 3

1 7

Venclexta

AbbVie

Phase 3

1 8

Paraplatin

AAvyxa

Phase 3

6 9

Opdualag

Bristol-Myers Squibb

Phase 2

3 10

Eloxatin

Teva

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2/3Active, not recruiting

Immunotherapy

NCT03686202

Clinical

Trials by Indication[1]

Head and Neck Squamous Cell Carcinoma1 trial

PembROlizumab With or Without Microbial EcOsystem ThErapeutic 4 (MET4) in Advanced Head and Neck Squamous Cell Carcinoma

Withdrawn·CCanadian Cancer Trials Group·Phase 2·NCT05743777

Immunotherapy1 trial

Feasibility Study of MET-4: Evaluating Fecal Microbiome Effects in Immunotherapy Patients

Active, not recruiting·UUniversity Health Network, Toronto·Phase 2/3·NCT03686202·65 enrolled

Squamous Cell Carcinoma1 trial

Role of Microbiome as a Biomarkers in Locoregionally-Advanced Oropharyngeal Squamous Cell Carcinoma 2

Active, not recruiting·UUniversity Health Network, Toronto·N/A·NCT03838601·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for MET-4. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MET-4 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MET-4. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Health Network, Toronto company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUniversity Health Network, Toronto

MET-4

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Head and Neck Squamous Cell Carcinoma1 trial

Immunotherapy1 trial

Squamous Cell Carcinoma1 trial

References

Drug Info

Quick Facts

Related News